StanfordMed Matters: GLP-1 Agonists for Obesity

Thursday, October 24, 2024, 12:00 PM - Friday, October 24, 2025, 11:59 AM, On Demand

Join Dr. Dan E. Azagury, Associate Professor of Surgery, Dr. Sun Kim, Associate Professor of Medicine (Endocrinology), and Dr. Janey Pratt, Clinical Professor of Surgery - Pediatric Surgery, at Stanford University for an informative session on obesity treatment and GLP-1 receptor agonist therapies. This episode explores the history, current guidelines, and groundbreaking future of GLP-1 treatments for pediatric and adult populations. Gain valuable insights into how GLP-1 therapies have transformed the landscape of obesity management and patient outcomes, and hear exclusive recommendations for clinicians treating obesity as a complex metabolic disease.

Release Date: October 24, 2024, 12:00 PM PT
Expiration Date: October 24, 2025, 11:59 AM PT
Estimated time to complete:~45 minutes
Registration Fee: free

Join the YouTube Premier Live on October 24, 2024 at noon PT to participate in the discussion and ask questions. The recording will remain online for those who couldn't attend live.

AMA PRA Category 1 Credits™ (0.75 hours), Non-Physician Participation Credit (0.75 hours)

1. Utilize current guidelines to treat and manage patients with obesity.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation 
American Medical Association (AMA) 
Stanford Medicine designates this Other Activity (Enduring Material and Live Activity) for a maximum of 0.75 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require accommodations, please contact the CME Office.

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: https://laneguides.stanford.edu/multicultural-health

References/Bibliography
1.Iqbal, J., Wu, H. X., Hu, N., Zhou, Y. H., Li, L., Xiao, F., Wang, T., Jiang, H. L., Xu, S. N., Huang, B. L., & Zhou, H. D. (2022). Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obesity reviews : an official journal of the International Association for the Study of Obesity, 23(6), e13435. https://doi.org/10.1111/obr.13435
2.Jensen, A. B., Renström, F., Aczél, S., Folie, P., Biraima-Steinemann, M., Beuschlein, F., & Bilz, S. (2023). Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study. Obesity surgery, 33(4), 1017–1025. https://doi.org/10.1007/s11695-023-06484-8
3.Lauder, L., Mahfoud, F., Azizi, M., Bhatt, D. L., Ewen, S., Kario, K., Parati, G., Rossignol, P., Schlaich, M. P., Teo, K. K., Townsend, R. R., Tsioufis, C., Weber, M. A., Weber, T., & Böhm, M. (2023). Hypertension management in patients with cardiovascular comorbidities. European heart journal, 44(23), 2066–2077. https://doi.org/10.1093/eurheartj/ehac395
4.Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., Ryan, D. H., & SELECT Trial Investigators (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
5.Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., Pratt, E., Kazda, C., Konig, M., & GZGI Investigators (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. The New England journal of medicine, 389(10), 877–888. https://doi.org/10.1056/NEJMoa2302392

For activity related questions, please contact
     Name: Alisa Richardson
     Title: Education Program Manager
     Email: [email protected]

For CME general questions, please contact 
     Email: [email protected]

Mitigation of Relevant Financial Relationships

Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity, except those listed in the table below. All of the relevant financial relationships listed for these individuals have been mitigated.